Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 18/20 | 0.81 |
| ▸ | TCF7L2 | Q9NQB0 | 18/20 | 0.81 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167914 | 1.00 | CTNNB1 (0.81) | CTNNB1TCF7L2RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4173139 | 0.93 | CTNNB1 (0.81) | CTNNB1TCF7L2RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4173134 | 0.93 | CTNNB1 (0.81) | CTNNB1TCF7L2RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4177604 | 0.93 | CTNNB1 (0.81) | CTNNB1TCF7L2RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4160415 | 0.90 | CTNNB1 (1.00) | CTNNB1TCF7L2RAB9ASMN1; SMN2 | |
| SCHEMBL4160413 | 0.90 | CTNNB1 (1.00) | CTNNB1TCF7L2RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4167592 | 0.89 | CTNNB1 (0.98) | CTNNB1TCF7L2RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4167586 | 0.89 | CTNNB1 (0.98) | CTNNB1TCF7L2RAB9ASMN1; SMN2 | |
| SCHEMBL4174191 | 0.85 | CTNNB1 (0.81) | CTNNB1TCF7L2RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4168616 | 0.82 | CTNNB1 (1.00) | CTNNB1TCF7L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090004185-A1 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | WYETH (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2008086462-A2 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | WYETH (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004185-A1 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | TCF4, CTNNB1, TCF7 | CTNNB1 2/4885TCF7L2 4/4885RAB9A 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.